Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors not yet approved by the MHRA or EMA for clinical use in the UK
Studies show that patients receiving 1.7 mg and 2.4 mg semaglutide lost 12.1% of their body weight in six months, whereas patients taking 0.5 mg, 1 mg, or 1.25 mg lost 9.2% of their total body weight
While it might not be the quickest option, consulting with your trusted physician is a great way to make sure youre making an informed and safe decision for your body
Reduces Inflammation: Chronic inflammation is at the root of many health problems, including skin conditions, joint pain, and cardiovascular diseases
PLAN + STATE RULES How Plan Type Affects Your Coverage How Plan Type Affects Your Coverage Your Zepbound coverage is shaped by two things working together: Your Plan Type who controls your benefits (your employer, government, etc) BCBS State Rules how strict your local BCBS company is by default These two things combine to create your actual coverage situation